A Study of SSS17 in Healthy Subjects

Summary

This is a first-in-human, Phase 1, single-center, randomized, single-blind, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, PD of SSS17 following oral administration in healthy subjects. Approximately 65 subjects (53 receiving active drug and 12 receiving placebo) will participate in this study.

Timeline

Start

2020-05-01

Primary completion

2021-06-30

Completion

2021-12-31

Drugs

Indications